LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,113
تعداد مقالات10,208
تعداد مشاهده مقاله40,780,110
تعداد دریافت فایل اصل مقاله8,803,917
Taghiloo, Saeid, Ajami, Abolghasem, Alizadeh-Navaei, Reza, Zaboli, Ehsan, Asgarian-Omran, Hossein. (1400). Treatment by PI3K/mTOR Inhibitor BEZ235 Combined with TLR-7/8 Agonist Interfere with Immune Evasion Mechanisms of WEHI-3 Mouse Leukemia Cells. سامانه مدیریت نشریات علمی, 19(1), 58-70. doi: 10.22034/iji.2022.92576.2155
Saeid Taghiloo; Abolghasem Ajami; Reza Alizadeh-Navaei; Ehsan Zaboli; Hossein Asgarian-Omran. "Treatment by PI3K/mTOR Inhibitor BEZ235 Combined with TLR-7/8 Agonist Interfere with Immune Evasion Mechanisms of WEHI-3 Mouse Leukemia Cells". سامانه مدیریت نشریات علمی, 19, 1, 1400, 58-70. doi: 10.22034/iji.2022.92576.2155
Taghiloo, Saeid, Ajami, Abolghasem, Alizadeh-Navaei, Reza, Zaboli, Ehsan, Asgarian-Omran, Hossein. (1400). 'Treatment by PI3K/mTOR Inhibitor BEZ235 Combined with TLR-7/8 Agonist Interfere with Immune Evasion Mechanisms of WEHI-3 Mouse Leukemia Cells', سامانه مدیریت نشریات علمی, 19(1), pp. 58-70. doi: 10.22034/iji.2022.92576.2155
Taghiloo, Saeid, Ajami, Abolghasem, Alizadeh-Navaei, Reza, Zaboli, Ehsan, Asgarian-Omran, Hossein. Treatment by PI3K/mTOR Inhibitor BEZ235 Combined with TLR-7/8 Agonist Interfere with Immune Evasion Mechanisms of WEHI-3 Mouse Leukemia Cells. سامانه مدیریت نشریات علمی, 1400; 19(1): 58-70. doi: 10.22034/iji.2022.92576.2155

Treatment by PI3K/mTOR Inhibitor BEZ235 Combined with TLR-7/8 Agonist Interfere with Immune Evasion Mechanisms of WEHI-3 Mouse Leukemia Cells

Iranian Journal of Immunology
دوره 19، شماره 1، خرداد 2022، صفحه 58-70    اصل مقاله (1.65 M)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22034/iji.2022.92576.2155
نویسندگان
Saeid Taghiloo1، 2؛ Abolghasem Ajami1؛ Reza Alizadeh-Navaei3؛ Ehsan Zaboli3؛ Hossein Asgarian-Omran* 1، 3
1Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
2Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
3Gastrointestinal Cancer Research Center, Non-Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
چکیده
Background: Several PI3K/Akt/mTOR pathway inhibitors and TLR agonists induce tumor cell death. However, the mechanisms of these therapeutic approaches in acute myeloid leukemia (AML) cells are still unknown. Objectives: To investigate the effects of BEZ235, as a dual inhibitor of PI3K and mTOR pathways, and TLR7/8 agonist R848 on the expression and regulation of the immune inhibitory molecules in myeloid leukemia cells. Methods: WEHI-3 leukemia cells were incubated with dual PI3K and mTOR inhibitor BEZ235 and TLR7/8 agonist R848 for 48 hrs. Firstly, cell viability was assessed by MTT method. The semi-quantitative relative mRNA expression of Galectin-9 (Gal-9), PD-L1, PVR, and STAT3 was assessed according to HPRT as a housekeeping gene. Finally, the protein expression of phosphorylated STAT3 was evaluated by western blotting analysis. Results: WEHI-3 cells showed growth inhibition following treatment with BEZ235 and R848 whose combination exerted more proliferation arrest. The mRNA expression of Gal-9, PD-L1 and PVR immune checkpoint molecules significantly reduced in treated cells with BEZ235 and R848. Combined treatment indicated more reduction compared with the single treatment. Finally, the expression and phosphorylation of STAT3 were down-regulated after a single or dual treatment with BEZ235 and R848. Conclusion: Our results conclude that treatment with the combination of BEZ235 and R848 interferes with immune evasion mechanisms through STAT3-signaling pathway in WEHI-3 leukemia cells.
کلیدواژه‌ها
AML؛ BEZ235؛ Immune Evasion؛ PI3K/mTOR؛ R848؛ TLR7/8 Agonist
آمار
تعداد مشاهده مقاله: 1,242
تعداد دریافت فایل اصل مقاله: 1,062


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب